Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin

Nephron
J S MałyszkoMichal Mysliwiec

Abstract

So far it is not clear how erythropoietin affects the anticoagulant properties of vascular endothelium in uremia. Since serotonin is also thought to play a role in the pathogenesis of thrombosis, the aim of the study was to evaluate major components of extrinsic coagulation pathway, markers of endothelial cell injury, lipoprotein (a) and peripheral serotonergic mechanisms during rHuEPO therapy in hemodialyzed patients. The study was performed on chronically hemodialyzed patients divided into two groups: with rHuEPO treatment and without rHuEPO therapy in relation to the control group. In uremic patients, thrombomodulin and von Willebrand factor, activity of factor VII, tissue factor pathway inhibitor (TFPI) activity, TFPI and tissue factor (TF) concentrations, lipoprotein (a) level were significantly higher when compared to healthy volunteers. Treatment with rHuEPO resulted in a further significant rise in markers of endothelial cell injury: thrombomodulin and von Willebrand factor and TFPI concentration. Extrinsic coagulation factors: activities of factor VII and X, TFPI activity and TF activity and concentration, lipoprotein (a) and vitronectin remained unchanged during rHuEPO therapy. Platelet serotonin content and whole blo...Continue Reading

Citations

Jun 15, 2006·Wiener klinische Wochenschrift·Walter H Hörl
May 20, 2003·Seminars in Dialysis·Liam F Casserly, Laura M Dember
May 2, 2003·Psychosomatics·Muhammad N MomenPeter F Buckley
Sep 29, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·I PietrzakD Zaremba-Drobnik
May 7, 2002·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Jacek Borawski, Michal Mysliwiec
Jan 9, 2003·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Jacek BorawskiMichal Mysliwiec
Jan 26, 2013·International Journal of Molecular Sciences·Maria Letizia TrincavelliClaudia Martini
Dec 5, 2003·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Ján Stasko, Peter Kubisz
Jun 1, 2003·Hemodialysis International·Sydney C W Tang, Kar Neng Lai

Related Concepts

Xa-dependent factor VIIa-TF inhibitor
Arteriosclerosis
Blood Coagulation
Blood Platelets
Endothelium, Vascular
Erythropoietin
Hemodialysis
Lipoproteins
Proteins, Recombinant DNA
Hydroxytryptamine

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Jacek BorawskiMichal Mysliwiec
Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Ján Stasko, Peter Kubisz
© 2021 Meta ULC. All rights reserved